Latest Market News

Ramsay Health Care has announced a fully franked ordinary dividend of AUD 0.40 per share for the six months ending June 2025, signaling steady returns for shareholders.

Greatland Resources Limited has reported a robust unaudited FY2025 result, generating $337.3 million net profit after tax from seven months of Telfer gold-copper mine operations, alongside a successful ASX listing and strong cash flow.

SomnoMed delivered a strong FY25 performance with revenue climbing 22% to $111.5 million and EBITDA turning positive at $9.2 million, boosted by operational improvements and FDA clearance of its Rest Assure device. The company projects further growth in FY26 with expanded manufacturing and ongoing innovation.

Raiz Invest Limited reported a robust FY25 with 15% revenue growth and a 147% jump in underlying EBITDA, driven by innovative products and AI-powered marketing. The company projects further earnings growth in FY26 amid expanding customer base and strategic partnerships.

Raiz Invest reported robust FY25 results with 15% revenue growth and a near break-even net loss, underpinned by strong customer and funds growth. The fintech’s strategic innovations and partnerships set a positive tone for FY26.

Raiz Invest Limited reported robust FY25 results with revenue up 14.5% and underlying EBITDA surging 147.5%, while completing its exit from Southeast Asia and launching the new Raiz Lite product.

Control Bionics Limited has announced a $2.06 million non-renounceable rights issue to fund the commercial expansion of its NeuroStrip device and bolster NeuroNode operations. The capital raise is underwritten to approximately $1.15 million by major shareholders and strategic partners.

SomnoMed has delivered a standout FY25 with revenue and EBITDA exceeding market expectations, driven by strong regional growth and operational improvements. The company is now expanding capacity and advancing its innovative Rest Assure device.

SomnoMed Limited reported a record FY25 with $111.5 million revenue and a return to positive EBITDA, marking a milestone of over one million patients treated globally. The company secured FDA clearance for its Rest Assure® compliance tracking device and provided optimistic guidance for FY26.

Invion Limited has affirmed its compliance with ASX disclosure rules following the US FDA’s granting of Orphan Drug Designation for its anal cancer treatment candidate INV043. The company detailed the timing and verification process behind its announcement.

Golden Horse Minerals’ latest Down Hole Electromagnetic survey at Hopes Hill reveals multiple large conductive anomalies, supported by recent high-grade drill results, signaling promising deeper gold mineralisation. Complementary soil geochemistry across regional prospects further sharpens drill targets.

Pengana Capital Group reported a strong turnaround in FY 2025 profitability, driven by a surge in private credit funds under management and successful new product launches. The firm’s strategic shift towards private markets is reshaping its revenue profile and balance sheet strength.